Skip to main content
. Author manuscript; available in PMC: 2022 Aug 4.
Published in final edited form as: Transplant Cell Ther. 2022 Apr 29;28(7):392.e1–392.e9. doi: 10.1016/j.jtct.2022.04.019

Table 1.

Demographic Characteristics of HSCT Recipients with Moderate Risk TA-TMA (N = 48)

Variable Value
Male sex, n (%) 23 (47.9)
Age at transplantation, yr, median (IQR) 7.3 (3.4–13)
Race, n (%)
 Caucasian 40 (85.1)
 African American 6 (12.8)
 Asian 0 (0)
 Mixed 1 (2.1)
Diagnostic group, n (%)
 Malignancy 16 (33.3)
 Immune deficiency 10 (20.8)
 Marrow failure 13 (27.1)
 Benign hematology 6 (12.5)
 Genetic/metabolic 3 (6.2)
Stem cell donor type, n (%)
 Related (MRD, MMRD) 13 (27.1)
 Unrelated (MUD, MMUD) 30 (62.5)
 Autologous 5 (10.4)
Stem cell source, n (%)
 Bone marrow 31 (64.6)
 Peripheral blood 15 (31.2)
 Cord blood 2 (4.2)
HLA match (allogeneic-HSCT only), n (%)
 Fully matched (MRD, MUD) 28 (65.1)
 Mismatched (MMR, MMUD, haploidentical) 15 (34.9)
Conditioning regimen type, n (%)
 Myeloablative 30 (62.5)
 Reduced intensity 18 (37.5)
GVHD prophylaxis (allogeneic HSCT only), n (%)
 CNIs 34 (81)
 T cell depletion 6 (10.7)

MRD indicates matched related donor; MMRD, mismatched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor.